{"nctId":"NCT00841672","briefTitle":"Efficacy and Safety of the Combination of Aliskiren (300 mg) and Amlodipine (10 mg) Compared to Amlodipine (10 mg) Monotherapy in Patients With Moderate to Severe Hypertension","startDateStruct":{"date":"2009-01"},"conditions":["Moderate to Severe Hypertension"],"count":485,"armGroups":[{"label":"Aliskiren/amlodipine 300/10 mg tablet","type":"EXPERIMENTAL","interventionNames":["Drug: Aliskiren/amlodipine 300/10 mg tablet"]},{"label":"Amlodipine 10 mg capsule","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Amlodipine 10 mg capsule"]}],"interventions":[{"name":"Aliskiren/amlodipine 300/10 mg tablet","otherNames":[]},{"name":"Amlodipine 10 mg capsule","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Outpatients ≥ 18 years of age\n* Patients with a diagnosis of moderate to severe hypertension, defined as msSBP ≥ 160 mmHg and \\< 200 mmHg at Visit 2\n\nExclusion Criteria:\n\n* Mild to moderate hypertension\n* Pregnant or nursing (lactating) women\n* Women of child-bearing potential\n* Previous or current diagnosis of heart failure New York Heart Association(NYHA) Class II-IV.\n* Serum potassium ≥ 5.3 mEq/L (mmol/L) at Visit 1.\n* Uncontrolled Type 1 or Type 2 diabetes mellitus\n* Hypersensitivity to renin inhibitors, calcium channel blockers, or to drugs with Similar chemical structures\n* History of hypertensive encephalopathy or cerebrovascular accident, or history of transient ischemic attack (TIA), myocardial infarction, coronary bypass surgery, or any percutaneous coronary intervention\n* Patients on a combination of 3 or more antihypertensive medications\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Sitting Systolic Blood Pressure (msSBP)","description":"Change in mean sitting systolic blood pressure (msSBP) from baseline to end of study (Week 8)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.72","spread":"0.937"},{"groupId":"OG001","value":"-30.63","spread":"0.941"}]}]}]},{"type":"SECONDARY","title":"Mean Sitting Diastolic Blood Pressure (msDBP)","description":"Change in mean sitting diastolic blood pressure (msDBP) from baseline to end of study (Week 8)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-16.10","spread":"0.557"},{"groupId":"OG001","value":"-12.27","spread":"0.559"}]}]}]},{"type":"SECONDARY","title":"Systolic Blood Pressure Response","description":"Percentage of patients achieving a mean sitting systolic blood pressure response (msSBP \\< 140 mmHg or a reduction =\\> 20 mmHg from the baseline) from baseline to end of study (Week 8)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.8","spread":null},{"groupId":"OG001","value":"79.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Diastolic Blood Pressure Response","description":"Percentage of patients achieving a mean sitting diastolic blood pressure response (msDBP \\< 90 mmHg or a reduction ≥ 10 mmHg from the baseline) from baseline to end of study (Week 8)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.7","spread":null},{"groupId":"OG001","value":"86.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Pressure Control","description":"Percentage of patients achieving blood pressure control (msSBP \\< 140 mm Hg and msDBP \\< 90 mm Hg) at end of study","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.0","spread":null},{"groupId":"OG001","value":"49.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":243},"commonTop":["Oedema peripheral","Headache"]}}}